Efficacy of Quantum Molecular Resonance Combined With Intense Pulsed Light in Mixed Dry Eye
Launched by UNIVERSITY OF SEVILLE · Aug 26, 2024
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
Study Title: Efficacy of Quantum Molecular Resonance Combined with Intense Pulsed Light in Mixed Dry Eye: A Prospective Clinical Study
Purpose of the Study: This study aims to evaluate how well two treatments-Quantum Molecular Resonance (QMR) and Intense Pulsed Light (IPL)-work when used together to treat Mixed Dry Eye (MDE). Mixed Dry Eye is a condition that affects both the quantity and quality of tears, leading to discomfort and vision problems. The goal is to see if combining these treatments can better relieve symptoms and improve tear production and stability.
What is Mixed Dry Eye?...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years or older
- • Diagnosed with Mixed Dry Eye (MDE)
- • Ocular Surface Disease Index (OSDI) score of 13 or higher
- • Non-Invasive Tear Film Break-Up Time (NIBUT) less than 10 seconds
- • Lipid Layer Thickness (LLT) less than 75 nm
- • Schirmer I Test (ST) without anesthesia less than 5 mm in 5 minutes
- Exclusion Criteria:
- • Presence of skin conditions that prevent QMR or IPL treatments
- * Corneal disorders that affect diagnostic tests, including:
- • Active corneal infections
- • Corneal dystrophies
- • Active ocular allergy
- * Previous device-based dry eye treatments, such as:
- • Microblepharoexfoliation
- • Low-level light therapy
- • Vectored thermal pulsation
- • Inability to understand or comprehend the informed consent
- • Pregnant or lactating women
- • Contact lens wearers who do not discontinue lens use at least one week before baseline and follow-up exams
About University Of Seville
The University of Seville is a prestigious academic institution dedicated to advancing knowledge through innovative research and exceptional education. With a strong emphasis on interdisciplinary collaboration, the university actively engages in clinical trials aimed at enhancing patient care and medical outcomes. Its commitment to rigorous scientific inquiry and ethical standards positions it as a leading sponsor in the field of clinical research, fostering partnerships with healthcare professionals and institutions to drive advancements in medical science and improve public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Girifalco, Catanzaro, Italy
Patients applied
Trial Officials
José-María Sánchez-González, OD, MsC, PhD
Study Chair
University of Seville
Carlos Rocha-de-Lossada, MD PhD
Study Director
University of Seville
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported